Due to the presence of multiple epigenetic abnormalities in cancer cells, we investigated the combined therapeutic value of 5-Aza-CdR and clorgyline to inhibit DNMTs and LSD1, in bladder cancer (T24), leukemia (HL60) and colorectal cancer (HCT116) cell lines. The gene discussed is KDM1A; the disease is leukemia.